Menu Search
Equities

Clinica las Condes SA

LASCONDES:SGO

Clinica las Condes SA

Actions
Health CareHealth Care Providers
  • Price (CLP)15,900.00
  • Today's Change-100.00 / -0.63%
  • Shares traded6.76k
  • 1 Year change+44.55%
  • Beta0.3081
Data delayed at least 20 minutes, as of May 03 2024 19:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clinica las Condes SA (CLC) is a Chile-based company engaged in the healthcare sector. CLC provides hospital and outpatient services, such as internal medicine admission and surgery, intensive and intermediate care units, pediatrics and neonatology, post-surgery recuperation, clinical laboratories, radiology, computerized tomography, magnetic resonance imaging (MRI), radiotherapy, nuclear medicine, ultrasonography, hemodialysis and other outpatient procedures and services that cover all areas of medicine. The Company owns direct and indirect subsidiaries, such as Diagnosticos por Imagenes Ltda, Servicios de Salud Integrados SA, Prestaciones Medicas Las Condes SA, Inmobiliaria CLC SA and Seguros CLC SA.

  • Revenue in CLP (TTM)202.26bn
  • Net income in CLP-3.40bn
  • Incorporated1979
  • Employees3.08k
More ▼

Institutional shareholders

0.47%Per cent of shares held by top holders
HolderShares% Held
Finaccess M�xico SA de CV SOSIas of 29 Feb 202431.88k0.38%
Dimensional Fund Advisors LPas of 04 Apr 20246.60k0.08%
Dimensional Fund Advisors Ltd.as of 29 Feb 2024466.000.01%
DFA Australia Ltd.as of 31 Dec 20233.000.00%
Credicorp Capital Asset Management SA AGFas of 31 Mar 20241.000.00%
More ▼
Data from 31 Dec 2023 - 02 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.